JZP458 receives CHMP recommendation for approval in ALL, lymphoblastic lymphoma

JZP458 receives CHMP recommendation for approval in ALL, lymphoblastic lymphoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of JZP458, a recombinant erwinia asparaginase or chrysantaspase, for use in combination with multiagent chemotherapy for the treatment of adult and pediatric patients 1 month of age and older with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have … Read more